mCRPC in focus
Transcript: The evolving treatment landscape for mCRPC
Professor Axel Merseburger
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
So, the main thing I could think of or recommend what specialists should consider when treating men with mCRPC, I think there are a lot of aspects. First, we need to see where we start, what the patient profile is. If we have low-volume, high-volume disease.
I know this is more in the mHSPC setting, but also in mCRPC, you treat a patient differently with liver disease who is 50, compared to somebody with like a couple of bone diseases, which is 85 years old.
So, I think this is something we need to take into consideration when we decide upon the treatment. And then, once we start, we have those options in chemotherapy, we have the options in hormone therapy, and as of yet, most men should receive at some point chemotherapy. And this needs to be discussed. Also, aside the sequencing question, treatment intensification, or maybe doublet therapy. And then also, educate the patient on those ADT backbone treatment that is recommended by the large guidelines, which are available. And then also, the imaging, and what imaging should be applied if it should be regular, standard conventional imaging, or a PSMA-PET, which is available in some countries already.
So, I think this needs to be taken into consideration, and especially when it comes to second and third-line treatment in mCRPC, when we have a very palliative setting. I think here we need to guide the patient and their carers and families. And on this palliative setting, and how we can as treating physician, nurses, study nurses, can support the life which we know will end pretty soon in most cases because of this aggressive prostate cancer disease.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.